RadNet Reports Third Quarter Financial Results Demonstrating Strong Recovery from the COVID-19 Impact
RadNet, Inc. (NASDAQ: RDNT) reported a 53.1% sequential increase in Total Net Revenue for Q3 2020, totaling $291.8 million, although this reflects a slight decrease of 0.3% year-over-year. Adjusted EBITDA reached $45.8 million, a 102.8% rise from Q2 2020 and up 11.7% from the previous year. The company recorded a Net Income of $6.2 million compared to a loss in Q2. The quarter saw a 66.2% increase in procedural volumes. Additionally, RadNet announced strategic partnerships to enhance growth prospects.
- Sequential Revenue increase of 53.1% ($101.2 million) from Q2 2020
- Adjusted EBITDA rose 102.8% from Q2 2020 ($23.2 million increase)
- Net Income increased by $16.8 million from Q2 2020
- Aggregate procedural volumes increased 66.2% from Q2 2020
- Cash balance of $89.7 million, undrawn on $195 million credit line
- Formation of joint ventures with Adventist Health and Dignity Health for strategic growth
- Total Revenue decreased 0.3% from Q3 2019
- MRI volume down 6.1% year-over-year
- Net Loss of $20.8 million for the nine months ended September 30, 2020
- Indicating a substantial recovery from the impact of COVID-19, Total Net Revenue (“Revenue”) was
$291.8 million in the third quarter of 2020, a sequential increase of53.1% from the second quarter of 2020 and a decrease of only0.3% from last year’s third quarter of$292.7 million - As a result of aggressive cost containment measures, Adjusted EBITDA(1) was
$45.8 million in the third quarter of 2020, a sequential increase of102.8% from the second quarter of 2020 and an increase of11.7% from last year’s third quarter Adjusted EBITDA(1) of$41.0 million
- Adjusted EBITDA(1) margin was
15.7% during the quarter as compared to14.0% in last year’s third quarter, an increase of 169 basis points (1.7% ) - Adjusting for the non-cash impact from the Company’s interest rate hedges on Net Income (“Adjusted Net Income”), Adjusted Net Income Per Share was
$0.15 in this year’s third quarter, as compared to Adjusted Net Loss Per share of$(0.16) in the second quarter of this year and Net Income Per Share of$0.06 in last year’s third quarter; this is a sequential increase of$0.31 per share from the second quarter of 2020 and$0.09 per share from last year’s third quarter
- Aggregate procedural volumes increased
66.2% from the second quarter of 2020 - At third quarter end, RadNet had a cash balance of
$89.7 million and was undrawn on its$195 million revolving line of credit
- Subsequent to quarter end, RadNet announced the formation of a joint venture with Adventist Health in Simi Valley, California and the creation of a new operating platform in Phoenix, Arizona with Dignity Health/CommonSpirit Health
LOS ANGELES, Nov. 09, 2020 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 334 owned and/or operated outpatient imaging centers, today reported financial results for its third quarter of 2020.
Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, “I am very pleased with our performance during the quarter. Our sequential improvement from the second quarter of 2020 is illustrative of both a strong recovery of our procedural volumes and our focus on controlling costs. Compared to the second quarter of this year, our Revenue grew
Dr. Berger continued, “COVID-19 necessitated that we evaluate every part of our business to reduce expenses and conserve cash. In addition to staffing, we addressed costs associated with purchasing, pre-authorization, scheduling, revenue cycle management, equipment service, facility rent, insurance and center-level operating protocols. The adjustments we made over the last six months have materially improved how we are delivering our services and have significantly increased operating margins. These enhancements should favorably contribute to our performance in the coming quarters, as increasing procedural volumes are anticipated if our country continues to recover from COVID-19.”
Dr. Berger added, “During the COVID-19 period, we temporarily closed facilities, suspended certain modalities at some facilities which remained open, consolidated patient volume into the centers of excellence, negotiated and restructured agreements with vendors and landlords and reduced employee costs through furloughs and temporary salary cuts, among other actions. Not only did these actions prove to secure our business in this difficult period, but they resulted in enhanced liquidity. We completed the third quarter with a cash balance of
“In October, we announced two partnerships that should further our strategic growth. First, we partnered with Adventist Health to create an outpatient imaging joint venture in Simi Valley, California to initially include three multimodality facilities and the management of the Nancy Reagan Breast Center. This affiliation with Adventist Health, one of the largest health systems on the West Coast and Hawaii, is scheduled to begin operations in January. Second, we created an operating platform in Phoenix, Arizona through a partnership with Dignity Health/CommonSpirit Health. Though this is our third partnership with Dignity, it is RadNet’s first entry into a new geography since we entered the New York City marketplace in 2013. We initially acquired eight Arizona facilities and, with Dignity, are committed to substantially growing the scope and breadth of this platform. Dignity will bring great value to the newly created partnership through its ownership of hospitals, medical groups and urgent care centers and its broad affiliations and relationships with physician practices in the Phoenix healthcare delivery system,” concluded Dr. Berger.
Third Quarter Financial Results
For the third quarter of 2020, RadNet reported Revenue of
Net Income increased
Affecting Net Income in the third quarter of 2020 were certain non-cash expenses or non-recurring items including:
For the third quarter of 2020, as compared to the prior year’s third quarter, MRI volume decreased
Nine Month Financial Results
For the nine months ended September 30, 2020, RadNet reported Revenue of
Affecting operating results in the nine months ended September 30, 2020 were certain non-cash expenses or non-recurring items including:
Conference Call for Today
Dr. Howard Berger, President and Chief Executive Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call to discuss its third quarter 2020 results on Monday, November 9th, 2020 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).
Conference Call Details:
Date: Monday, November 9, 2020
Time: 10:30 a.m. Eastern Time
Dial In-Number: 866-248-8441
International Dial-In Number: 786-204-3966
It is recommended that participants dial in approximately 5 to 10 minutes prior to the start of the 10:30 a.m. call. There will also be simultaneous and archived webcasts available at http://public.viavid.com/index.php?id=142324
or http://www.radnet.com under the “Investors” menu section and “News Releases” sub-menu of the website. An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode 9769738.
About RadNet, Inc.
RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 334 owned and/or operated outpatient imaging centers. RadNet's core markets include California, Maryland, Delaware, New Jersey, New York and Arizona. In addition, RadNet provides radiology information technology solutions, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of approximately 8,600 employees. For more information, visit http://www.radnet.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are expressions of our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Forward-looking statements in this press release include, among others, statements we make regarding response to and the expected future impacts of COVID-19, including statements about our anticipated business results, balance sheet and liquidity and our future liquidity, burn rate and our continuing ability to service or refinance our current indebtedness.
Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:
- the ongoing impact of the COVID-19 pandemic on our business, suppliers, payors, customers, referral sources, partners, patients and employees, including (i) government’s unprecedented action regarding existing and potential restrictions and/or obligations related to citizen and business activity to contain the virus; (ii) the consequences of an economic downturn resulting from the impacts of COVID-19 and the possibility of a global economic recession; (iii) the impact of the volume of canceled or rescheduled procedures, whether as a result of government action or patient choice; (iv) measures we are taking to respond to the COVID-19 pandemic, including changes to business practices; (v) the impact of government and administrative regulation, guidance and appropriations; (vi) changes in our revenues due to declining patient procedure volumes, changes in payor mix; (vii) potential increased expenses or workforce disruptions related to our employees that could lead to unavailability of key personnel; (viii) workforce disruptions related to our key partners, suppliers, vendors and others we do business with; (ix) the impact of return to work orders in certain states in which we operate; and (x) increased credit and collectability risks;
- the availability and terms of capital to fund our business;
- our ability to service our indebtedness, make principal and interest payments as those payments become due and remain in compliance with applicable debt covenants, in addition to our ability to refinance such indebtedness on acceptable terms;
- changes in general economic conditions nationally and regionally in the markets in which we operate;
- the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities;
- our ability to maintain our current credit rating and the impact on our funding costs and competitive position if we do not do so;
- volatility in interest and exchange rates, or credit markets;
- the adequacy of our cash flow and earnings to fund our current and future operations;
- changes in service mix, revenue mix and procedure volumes;
- delays in receiving payments for services provided;
- increased bankruptcies among our partner physicians or joint venture partners;
- the impact of the political environment and related developments on the current healthcare marketplace and on our business, including with respect to the future of the Affordable Care Act;
- the extent to which the ongoing implementation of healthcare reform, or changes in or new legislation, regulations or guidance, enforcement thereof by federal and state regulators or related litigation result in a reduction in coverage or reimbursement rates for our services, or other material impacts to our business;
- closures or slowdowns and changes in labor costs and labor difficulties, including stoppages affecting either our operations or our suppliers' abilities to deliver supplies needed in our facilities;
- the occurrence of hostilities, political instability or catastrophic events;
- the emergence or reemergence of and effects related to future pandemics, epidemics and infectious diseases; and
- noncompliance by us with any privacy or security laws or any cybersecurity incident or other security breach by us or a third party involving the misappropriation, loss or other unauthorized use or disclosure of confidential information.
Any forward-looking statement contained in this current report is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that we may make from time to time, whether as a result of changed circumstances, new information, future developments or otherwise, except as required by applicable law.
Regulation G: GAAP and Non-GAAP Financial Information
This release contains certain financial information not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results. The Company believes that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance. The Company believes this information is useful to investors and other interested parties because it removes unusual and nonrecurring charges that occur in the affected period and provides a basis for measuring the Company's financial condition against other quarters. Such information should not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Reconciliation of this information to the most comparable GAAP measures is included in this release in the tables which follow.
CONTACTS:
RadNet, Inc.
Mark Stolper, 310-445-2800
Executive Vice President and Chief Financial Officer
| RADNET, INC. AND SUBSIDIARIES | ||||||||||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||||||||||
| (IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA) | ||||||||||||||||
| September 30, 2020 | December 31, 2020 | |||||||||||||||
| (unaudited) | ||||||||||||||||
| ASSETS | ||||||||||||||||
| CURRENT ASSETS | ||||||||||||||||
| Cash and cash equivalents | $ | 89,739 | $ | 40,165 | ||||||||||||
| Accounts receivable | 137,411 | 154,763 | ||||||||||||||
| Due from affiliates | 424 | 1,242 | ||||||||||||||
| Prepaid expenses and other current assets | 31,482 | 45,004 | ||||||||||||||
| Total current assets | 259,056 | 241,174 | ||||||||||||||
| PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS | ||||||||||||||||
| Property and equipment, net | 361,950 | 367,795 | ||||||||||||||
| Operating lease right-of-use assets | 451,613 | 445,477 | ||||||||||||||
| Total property, equipment and right-of-use assets | 813,563 | 813,272 | ||||||||||||||
| OTHER ASSETS | ||||||||||||||||
| Goodwill | 470,685 | 441,973 | ||||||||||||||
| Other intangible assets | 57,152 | 42,994 | ||||||||||||||
| Deferred financing costs | 1,944 | 1,559 | ||||||||||||||
| Investment in joint ventures | 35,571 | 34,470 | ||||||||||||||
| Deferred tax assets, net of current portion | 42,188 | 34,548 | ||||||||||||||
| Deposits and other | 37,707 | 36,996 | ||||||||||||||
| Total assets | $ | 1,717,866 | $ | 1,646,986 | ||||||||||||
| LIABILITIES AND EQUITY | ||||||||||||||||
| CURRENT LIABILITIES | ||||||||||||||||
| Accounts payable, accrued expenses and other | $ | 205,701 | $ | 207,585 | ||||||||||||
| Due to affiliates | 12,287 | 14,347 | ||||||||||||||
| Deferred revenue | 45,846 | 1,316 | ||||||||||||||
| Current finance lease liability | 3,041 | 3,283 | ||||||||||||||
| Current operating lease liability | 67,449 | 61,206 | ||||||||||||||
| Current portion of notes payable | 39,463 | 39,691 | ||||||||||||||
| Total current liabilities | 373,787 | 327,428 | ||||||||||||||
| LONG-TERM LIABILITIES | ||||||||||||||||
| Long-term finance lease liability | 1,108 | 3,264 | ||||||||||||||
| Long-term operating lease liability | 428,233 | 420,922 | ||||||||||||||
| Notes payable, net of current portion | 627,179 | 652,704 | ||||||||||||||
| Other non-current liabilities | 41,438 | 9,529 | ||||||||||||||
| Total liabilities | 1,471,745 | 1,413,847 | ||||||||||||||
| EQUITY | ||||||||||||||||
| Common stock - $.0001 par value, 200,000,000 shares authorized; 51,596,098 and 50,314,328 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively | 5 | 5 | ||||||||||||||
| Additional paid-in-capital | 306,079 | 262,865 | ||||||||||||||
| Accumulated other comprehensive loss | (24,923 | ) | (8,026 | ) | ||||||||||||
| Accumulated deficit | (123,956 | ) | (103,159 | ) | ||||||||||||
| Total RadNet, Inc.'s stockholders' equity | 157,205 | 151,685 | ||||||||||||||
| Noncontrolling interests | 88,916 | 81,454 | ||||||||||||||
| Total equity | 246,121 | 233,139 | ||||||||||||||
| Total liabilities and equity | $ | 1,717,866 | $ | 1,646,986 | ||||||||||||
| RADNET, INC. AND SUBSIDIARIES | |||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| (IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA) | |||||||||||||||
| (unaudited) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||
| REVENUE | |||||||||||||||
| Service fee revenue | $ | 256,730 | $ | 261,908 | $ | 660,760 | 762,751 | ||||||||
| Revenue under capitation arrangements | 35,046 | 30,784 | 103,145 | 90,587 | |||||||||||
| Total service revenue | 291,776 | 292,692 | 763,905 | 853,338 | |||||||||||
| Provider relief funding | 221 | - | 25,696 | - | |||||||||||
| OPERATING EXPENSES | |||||||||||||||
| Cost of operations, excluding depreciation and amortization | 246,462 | 254,383 | 708,095 | 743,997 | |||||||||||
| Depreciation and amortization | 21,247 | 20,490 | 64,536 | 60,193 | |||||||||||
| Loss on sale and disposal of equipment and other | 342 | 917 | 543 | 1,990 | |||||||||||
| Severance costs | 571 | 52 | 1,647 | 1,054 | |||||||||||
| Total operating expenses | 268,622 | 275,842 | 774,821 | 807,234 | |||||||||||
| INCOME FROM OPERATIONS | 23,375 | 16,850 | 14,780 | 46,104 | |||||||||||
| OTHER INCOME AND EXPENSES | |||||||||||||||
| Interest expense | 11,061 | 11,895 | 33,443 | 36,589 | |||||||||||
| Equity in earnings of joint ventures | (2,276 | ) | (1,955 | ) | (5,176 | ) | (6,072 | ) | |||||||
| Non-cash change in fair value of interest rate hedge | 679 | - | 4,523 | - | |||||||||||
| Other (income) expenses | (139 | ) | 2 | (247 | ) | 1,271 | |||||||||
| Total other expenses | 9,325 | 9,942 | 32,543 | 31,788 | |||||||||||
| INCOME (LOSS) BEFORE INCOME TAXES | 14,050 | 6,908 | (17,763 | ) | 14,316 | ||||||||||
| (Provision for) benefit from income taxes | (3,825 | ) | (1,816 | ) | 5,029 | (3,556 | ) | ||||||||
| NET INCOME (LOSS) | 10,225 | 5,092 | (12,734 | ) | 10,760 | ||||||||||
| Net income attributable to noncontrolling interests | 4,069 | 1,897 | 8,063 | 6,400 | |||||||||||
| NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS | $ | 6,156 | $ | 3,195 | $ | (20,797 | ) | $ | 4,360 | ||||||
| BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS | $ | 0.12 | $ | 0.06 | $ | (0.41 | ) | $ | 0.09 | ||||||
| DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS | $ | 0.12 | $ | 0.06 | $ | (0.41 | ) | $ | 0.09 | ||||||
| WEIGHTED AVERAGE SHARES OUTSTANDING | |||||||||||||||
| Basic | 51,358,603 | 49,807,460 | 50,746,380 | 49,597,138 | |||||||||||
| Diluted | 51,955,815 | 50,360,360 | 50,746,380 | 50,113,306 | |||||||||||
| RADNET, INC. AND SUBSIDIARIES | |||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASHFLOWS | |||||||
| (IN THOUSANDS) | |||||||
| (unaudited) | |||||||
| Nine Months Ended September 30, | |||||||
| 2020 | 2019 | ||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | |||||||
| Net (loss) income | $ | (12,734 | ) | $ | 10,760 | ||
| Adjustments to reconcile net (loss) income to net cash provided by operating activities: | |||||||
| Depreciation and amortization | 64,536 | 60,193 | |||||
| Amortization of operating lease assets | 50,769 | 49,948 | |||||
| Equity in earnings of joint ventures,net of dividends | 530 | (2,148 | ) | ||||
| Amortization deferred financing costs and loan discount | 3,266 | 3,103 | |||||
| Loss on sale and disposal of equipment and other | 543 | 1,990 | |||||
| Amortization of cash flow hedge, net of taxes | 1,861 | - | |||||
| Non-cash change in fair value of interest rate hedge | 4,523 | - | |||||
| Stock-based compensation | 10,144 | 6,963 | |||||
| Other noncash item included in cost of operations | - | (559 | ) | ||||
| Change in fair value of contingent consideration | (145 | ) | (1,749 | ) | |||
| Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions: | |||||||
| Accounts receivable | 17,380 | (3,467 | ) | ||||
| Other current assets | 13,522 | (1,569 | ) | ||||
| Other assets | (700 | ) | (5,770 | ) | |||
| Deferred taxes | (7,640 | ) | (4,230 | ) | |||
| Operating leases | (43,351 | ) | (49,721 | ) | |||
| Deferred revenue | 44,530 | (490 | ) | ||||
| Accounts payable, accrued expenses and other | 23,309 | 19,349 | |||||
| Net cash provided by operating activities | 170,343 | 82,603 | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES | |||||||
| Purchase of imaging facilities and other acquisitions | (10,125 | ) | (27,150 | ) | |||
| Equity investments at fair value | - | (143 | ) | ||||
| Purchase of property and equipment | (77,303 | ) | (68,269 | ) | |||
| Proceeds from sale of equipment | 779 | 760 | |||||
| Proceeds from sale of equity interests in a joint venture | - | 132 | |||||
| Nulogix return of capital | - | 792 | |||||
| Equity contributions in existing joint ventures | (1,631 | ) | (103 | ) | |||
| Net cash used in investing activities | (88,280 | ) | (93,981 | ) | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | |||||||
| Principal payments on notes and leases payable | (2,704 | ) | (4,778 | ) | |||
| Payments on Term Loan Debt | (32,472 | ) | (29,918 | ) | |||
| Additional deferred finance costs on revolving loan amendment | (741 | ) | - | ||||
| Proceeds from issuance of new debt, net of issuing costs | - | 97,144 | |||||
| Proceeds from Payment Protection Program | 4,023 | - | |||||
| Distributions paid to noncontrolling interests | (601 | ) | (1,818 | ) | |||
| Proceeds from sale of noncontrolling interest | - | 5,275 | |||||
| Contribution from a noncontrolling partners | - | 750 | |||||
| Proceeds from revolving credit facility | 250,900 | 251,200 | |||||
| Payments on revolving credit facility | (250,900 | ) | (279,200 | ) | |||
| Proceeds from issuance of common stock upon exercise of options | - | 50 | |||||
| Net cash (used in) provided by financing activities | (32,495 | ) | 38,705 | ||||
| EFFECT OF EXCHANGE RATE CHANGES ON CASH | 6 | (28 | ) | ||||
| NET INCREASE IN CASH AND CASH EQUIVALENTS | 49,574 | 27,299 | |||||
| CASH AND CASH EQUIVALENTS, beginning of period | 40,165 | 10,389 | |||||
| CASH AND CASH EQUIVALENTS, end of period | $ | 89,739 | $ | 37,688 | |||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | |||||||
| Cash paid during the period for interest | $ | 31,210 | $ | 36,058 | |||
RADNET, INC.
RECONCILIATION OF GAAP NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON SHAREHOLDERS TO ADJUSTED EBITDA(1)
(IN THOUSANDS)
| Three Months Ended | ||||||||
| September 30, | ||||||||
| 2020 | 2019 | |||||||
| Net Income Attributable to RadNet, Inc. Common Shareholders | $ | 6,156 | $ | 3,195 | ||||
| Plus Interest Expense | 11,061 | 11,895 | ||||||
| Plus Provision for Income Taxes | 3,825 | 1,816 | ||||||
| Plus Depreciation and Amortization | 21,247 | 20,490 | ||||||
| Plus Loss on Sale of Equipment | 342 | 917 | ||||||
| Plus Severance Costs | 571 | 52 | ||||||
| Plus Non-cash Change in Fair Value of Interest Rate Hedge | 679 | - | ||||||
| Plus Other (Gains) Expenses | (139 | ) | 2 | |||||
| Plus Non-Cash Employee Stock-Based Compensation | 2,067 | 1,381 | ||||||
| Plus Legal Settlements | 1,248 | |||||||
| Adjusted EBITDA(1) | $ | 45,809 | $ | 40,996 | ||||
| Nine Months Ended | ||||||||
| September 30, | ||||||||
| 2020 | 2019 | |||||||
| Net (Loss) Income Attributable to RadNet, Inc. Common Shareholders | $ | (20,797 | ) | $ | 4,360 | |||
| Plus Interest Expense | 33,443 | 36,589 | ||||||
| Plus (Benefit From) Provision for Income Taxes | (5,029 | ) | 3,557 | |||||
| Plus Depreciation and Amortization | 64,536 | 60,193 | ||||||
| Plus Loss on Sale of Equipment | 543 | 1,989 | ||||||
| Plus Severance Costs | 1,647 | 1,054 | ||||||
| Plus Non-cash Change in Fair Value of Interest Rate Hedge | 4,523 | - | ||||||
| Plus Other (Gains) Expenses | (247 | ) | 1,271 | |||||
| Plus Non-Cash Employee Stock-Based Compensation | 10,144 | 6,964 | ||||||
| Plus Legal Settlements | - | 1,248 | ||||||
| Adjusted EBITDA(1) | $ | 88,763 | $ | 117,225 | ||||
| PAYOR CLASS BREAKDOWN | |||
| Third Quarter | |||
| 2020 | |||
| Commercial Insurance/Other Patient Revenue | 57.9 | % | |
| Medicare | 21.5 | % | |
| Capitation | 12.0 | % | |
| Workers Compensation/Personal Injury | 2.5 | % | |
| Medicaid | 2.4 | % | |
| Other/Non Patient | 3.7 | % | |
| Total | 100.0 | % | |
| RADNET PAYMENTS BY MODALITY | ||||||||||||
| Third Quarter | Full Year | Full Year | Full Year | |||||||||
| 2020 | 2019 | 2018 | 2017 | |||||||||
| MRI | 35.1 | % | 35.8 | % | 35.2 | % | 34.9 | % | ||||
| CT | 17.3 | % | 16.9 | % | 16.5 | % | 16.2 | % | ||||
| PET/CT | 5.8 | % | 5.6 | % | 5.7 | % | 5.2 | % | ||||
| X-ray | 7.2 | % | 8.1 | % | 8.4 | % | 8.9 | % | ||||
| Ultrasound | 12.4 | % | 12.4 | % | 12.2 | % | 12.1 | % | ||||
| Mammography | 16.5 | % | 15.2 | % | 15.8 | % | 16.3 | % | ||||
| Nuclear Medicine | 0.9 | % | 1.0 | % | 1.1 | % | 1.1 | % | ||||
| Other | 4.7 | % | 4.9 | % | 5.1 | % | 5.2 | % | ||||
| 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | |||||
Footnotes
(1) The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations and adjusted for losses or gains on the sale of equipment, other income or loss, transaction expenses, debt extinguishments and non-cash equity compensation. Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries, and is adjusted for non-cash or extraordinary and one-time events taken place during the period.
Adjusted EBITDA is reconciled to its nearest comparable GAAP financial measure. Adjusted EBITDA is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.
FAQ
What were RadNet's Q3 2020 revenue figures?
How much did RadNet's adjusted EBITDA increase in Q3 2020?
What is the net income reported by RadNet for Q3 2020?
What strategic partnerships did RadNet announce?
How did procedural volumes change for RadNet in Q3 2020?
